Loading…
Lobbying Spend
—
Filings
23
Firms Hired
2
Active Period
1999–2009
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $20,000
Matched citations: H. Con. Res. 342
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $20,000
Matched citations: H. Con. Res. 342
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $20,000
Matched citations: H. Con. Res. 342
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $20,000
Matched citations: S. Con. Res. 88
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $20,000
Matched citations: S. Con. Res. 88
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · fourth_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $20,000
Matched citations: S. Con. Res. 88
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $60,000
Matched citations: H. Con. Res. 342
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $60,000
Matched citations: H. Con. Res. 342
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $60,000
Matched citations: H. Con. Res. 342
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $60,000
Matched citations: S. Con. Res. 88
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $60,000
Matched citations: S. Con. Res. 88
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · third_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $60,000
Matched citations: S. Con. Res. 88
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · second_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $60,000
Matched citations: H. Con. Res. 342
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · second_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $60,000
Matched citations: H. Con. Res. 342
Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · second_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $60,000
Matched citations: H. Con. Res. 342
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · second_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $60,000
Matched citations: S. Con. Res. 88
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · second_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $60,000
Matched citations: S. Con. Res. 88
A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
2008 · second_quarter · Firm: PARRY, ROMANI, DECONCINI & SYMMS
Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens (see next page). Support of H. Con. Res. 342, Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in House), and Support of S. Con. Res. 88, Support of Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest. (Introduced in Senate)
Client expense: — · Firm income: $60,000
Matched citations: S. Con. Res. 88
Food and Drug Administration Amendments Act of 2007
2007 · year_end · Firm: PARRY, ROMANI, DECONCINI & SYMMS
S.1082, Amending the Federal Food, Drug, and Cosmetic Act & the Public Health Service Act H.R.2900, the FDA Amendment of 2007
Client expense: — · Firm income: $100,000
Matched citations: H.R.2900
Food and Drug Administration Amendments Act of 2007
2007 · mid_year · Firm: PARRY, ROMANI, DECONCINI & SYMMS
S.1082, Amending the Federal Food, Drug, and Cosmetic Act & the Public Health Service Act H.R.2900, the FDA Amendment of 2007
Client expense: — · Firm income: $100,000
Matched citations: H.R.2900
Source: Senate LDA